MET and non-small cell lung carcinoma: Further insight into the role of ICIs in MET-altered NSCLC comes from a case series of 24 patients with MET exon 14 skipping mutations and PD-L1 expression above 50%: these patients, treated with first-line pembrolizumab, achieved an ORR of 43%, a median PFS of 3.5 months, and an OS of 12.1 months, underscoring the potential utility of immunotherapy in select subpopulations [131].